Tuzistra XR Approval History
- FDA approved: Yes (First approved April 30th, 2015)
- Brand name: Tuzistra XR
- Generic name: chlorpheniramine polistirex and codeine polistirex
- Dosage form: Extended Release Oral Suspension
- Company: Vernalis plc and Tris Pharma Inc.
- Treatment for: Cold Symptoms, Cough
Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) is an extended-release opiate agonist antitussive and histamine-1 (H1) receptor antagonist combination indicated for the relief of cough and symptoms associated with upper respiratory allergies or the common cold.
Development History and FDA Approval Process for Tuzistra XR
|May 1, 2015||Vernalis and Tris Pharma Receive FDA Approval for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex)|
|Sep 15, 2014||FDA accepts Tuzistra XR (CCP-01) NDA for full review|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.